Prabhu Kuppuraj’s Post

LP (a) screening is important to identify cardiovascular risk, such as ASCVD. Laboratory lipid panel screening does not include LP (a) - it has to be ordered separately. The test is called: ADVANCED LIPID PANEL, CARDIO IQ® LIPOPROTEIN (a) Reference Range: <75 nmol/L Risk: Optimal <75 nmol/L Moderate 75-125 nmol/L High >125 nmol/L. Cardiovascular event risk category cut points (optimal, moderate, high) are based on Tsimika S. JACC 2017;69:692-711.

If you missed our latest live webinar on NT-proBNP, you can still catch up on this valuable discussion! “The clinical evolution of NT-proBNP: from diagnosis and prognosis to guiding therapy,” presented by Christopher R. deFilippi, MD, FACC of the Inova Heart and Vascular Institute is an exploration of the crucial role NT-proBNP plays in the diagnosis and management of heart failure (HF), as well as the implications of NT-proBNP levels in the context of other cardiovascular disease. To learn how treatments such as the use of sacubitril-valsartan influence NT-proBNP levels and how these changes can guide the optimization of treatment to reduce hospitalization and mortality rates, view the webinar recording here: https://bit.ly/4bYRsld

Cleerly's coronary artery disease (CAD) staging system has scored an FDA breakthrough device designation to analyse actionable features of coronary atherosclerosis, stenosis and ischaemia. https://lnkd.in/dBdcanAY #artificialintelligence #Cleerly #coronaryarterydisease #FDA #healthtech #heartdisease #regulatoryaffairs

Even believing 100% who knows the patients experience living with a disease or condition is the Patient Community, it is with Data that they will be able to fight for their needs. Evidence generation is key for the patient community. ISPOR ✅ EAS ✅ More to come! 😉 #patientengagement #patientdatageneration #hearthealth #empowercommunity #partnership

Today, our Executive Director, Neil Johnson, proudly presented an e-poster at the European Society of Cardiology’s Congress in London on Global Heart Hub’s patient-led study, Insights from Patients living with Elevated Cholesterol (IPEC).    It is a tremendous achievement to have the patient perspective included at such a prestigious international scientific meeting.   The IPEC e-poster focuses on the importance of the first discussion between a patient and their healthcare professional after diagnosis of hypercholesterolemia and how that interaction could help change the course of atherosclerotic cardiovascular disease (#ASCVD), the leading cause of mortality worldwide.     View our ESC poster now - https://lnkd.in/gm2AqrPn #ESCCongress #IPEC #PatientInsights #LDLCholesterol

NATROX® O₂ can be used during any phase of healing and can help patients with the following underlying conditions: ✅  Atherosclerosis ✅  Chronic wound inflammation ✅  Diabetes ✅  Immobility ✅  Immunosuppressed ✅  Microvascular disease ✅  Peripheral arterial disease (PAD), Macrovascular disease ✅  Systemic disease ✅  Venous disease Studies have shown NATROX® O₂ to be effective in healing previously non-healing diabetic foot ulcers, as shown in the graphic. Please visit our website for more information. Serena, T.E., Bullock, N.M., Cole, W., et al., 2021. Topical oxygen therapy in the treatment of diabetic foot ulcers: a multicentre, open randomized controlled clinical trial. J Wound Care, 30(5) supp.7-14 #PainManagement #HealthcareInnovation #PatientFirst

Half a billion patients worldwide are living with cardiovascular disease. Digital can enhance their treatment and improve their quality of life, while driving value for #biopharma companies. Learn more in our white paper, Leveraging digital to drive value for your cardiovascular therapies: https://lnkd.in/g4gaJPay #cardiovasculardisease #digitalhealth #brightinsight

Natrox O2 can not only heal wounds but save the NHS money. We were doing the sums earlier and a patient visiting clinic 10-12 times could potentially cost in the region of £1500-1700 in clinic and clinician fees. That doesn’t include dressings, medications etc. According to our figures, Natrox O2 costs around 1/3 of the above figure! Simply designed to heal wounds and save money. #woundcare #dfu #diabeticfoot #revolution #costbenefit

SCAI's new Secondary #Prevention for Atherosclerotic Cardiovascular Disease Toolkit explores gaps in #ASCVD care and how interventional cardiologists can address those gaps by applying guideline-directed care. Learn more ➡️ https://lnkd.in/gVM4cmNE #InterventionalCardiology

As part of HeartFlow’s commitment to investing in clinical evidence, we are excited to announce the expansion of the DECIDE Registry to ~20,000 patients across ~40 sites, now including asymptomatic patients and those with prior PCI. As the largest prospective study of its kind, the DECIDE Registry will provide crucial multi-site, real-world data to understand how HeartFlow Plaque Analysis influences medical management decisions and clinical outcomes for those with suspected coronary artery disease. Together, we’re paving the way to improved patient outcomes through enhanced insights and more personalized cardiovascular disease care: https://bit.ly/4dVH8fC. #HeartFlow #DECIDERegistry #HeartFlowPlaqueAnalysis #Plaque